CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PFE

Abrocitinib

Phase 3
PFIZER (PFE)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q2 '27
PFEPhase 3

Abrocitinib Phase 3 Est. Readout

Abrocitinib
Q2 2027~Q
CT.gov
00%
Drug Information

Target Indication

Atopic Dermatitis

Clinical Trial

NCT06807281

Last updated: 1/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA12/9/2021

Cibinqo

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.